Domainex Ltd has developed a number of chemical series with potent and selective activity against two closely related kinases TBK1 and IKK- epsilon.
5th November 2012
6th August 2012
Domainex and Horizon announce collaboration in support of Domainex's TBK1/IKKe Inhibitor Program.
2nd August 2012
Domainex successful in securing Biomedical Catalyst Feasibility Award
12th March 2012
Combinatorial domain hunting technology aids identification of MEK protein suitable for structure-based drug discovery New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK
6th January 2012
Download Press release